Functional heartburn (FH) is a common disorder that accounts for 30% to 50% of the patients with nonerosive reflux disease. FH is composed from a heterogeneous group of patients. They primarily include the hypersensitive and the nonacid sensitive esophagus. The mechanisms responsible for pain, clinical characteristics, and the optimal therapeutic approach of FH remain to be fully elucidated. Symptom response rate to potent antireflux treatment is significantly lower in FH patients as compared with any other gastroesophageal reflux disease (GERD) group, suggesting that in proton pump inhibitor (PPI) non-responders mechanisms other than acid reflux are likely the cause of symptoms. Patients with FH should be approached therapeutically as patients with GERD and should initially receive antireflux medications. Due to the need for profound acid suppression in this group of patients, PPIs should be considered relatively early in their care. Failure to respond to standard dosage of PPI is common and will require doubling the dose. If patients continue to report heartburn symptoms while receiving PPI twice daily, adding or switching to pain modulators/visceral analgesics is an appropriate therapeutic approach. Data about the usage of other therapeutic modalities in FH such as antireflux surgery, endoscopic treatment for GERD, and psychotherapy are still unavailable. Emerging treatment will likely include novel pain modulators and more effective antireflux medications.
KeywordsOmeprazole Proton Pump Inhibitor Proton Pump Inhibitor Therapy Tegaserod Esophageal Acid Exposure
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Klinkenberg-Knol EC, Castell DO: Clinical spectrum and diagnosis of gastroesophageal reflux disease. In The Esophagus. 3rd ed. Castell DO, Richter JE, editors. Philadelphia: Lippincott Williams and Wilkins 1999, 75–380.Google Scholar
- 3.Lind T, Havelund T, Carlsson R: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997, 32: 974–979. An important paper that describes the symptom response rate of functional heartburn patients to PPI therapy as compared to NERD patients with abnormal pH values.PubMedCrossRefGoogle Scholar
- 10.Weiner GJ, Morgan TM, Copper JB, et al.: The symptom index: A clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 1988, 83: 358–361.Google Scholar
- 14.Hobson AR, Matthews P, Furlong P, Aziz Q: The role of esophageal afferent pathway sensitivity in non-erosive reflux disease (abstract). Gastroenterology 2004, 126: A-18, 128.Google Scholar
- 22.Fass R, Murthy U, Hayden CW, et al.: Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-esophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000, 14: 1595–1603.PubMedCrossRefGoogle Scholar
- 28.Fenton P, Terry ML, Galloway KD, et al.: Is there a role for laparoscopic fundoplication in patients with non-erosive reflux disease (NERD)? (abstract). Gastroenterology 2000, 18: A481, 2600.Google Scholar